Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 3, 1997

View Archived Issues

Japanese researchers focus on pyripyropenes

Prenyl-protein transferase inhibitors reported by Merck & Co.

Novel cephalosporins reported by Japanese investigators

Nippon Zoki claims aFGF fragments for CNS indications

New vitamin D derivatives from Duphar

Lilly claims IGF-1 superagonists

New AIDS vaccine candidates reported by Institut Pasteur

Fluoxetine plus dexfenfluramine effective in obese patients

Another new application for botulinum toxin reported in the literature

TxA2 antagonists modulate tumor sensitivity to platinum anticancer drugs

Ciprofloxacin ophthalmic solution effective in treating bacterial corneal ulcers

Lipid effects of two gestodene/ethinylestradiol combinations compared

German investigators present potent dopamine D1 antagonist

Two FDA approvals for Taro

Watson/Royce merger approved

Watson's first NDA product approved

FDA advisory panel to discuss penile implant guidelines

Andrx freed to market Dilacor XR bioequivalent

bFGF enters clinical trials for PVD

Generic antidiabetic agent approved by FDA

New HRT patch approved for launch in U.S.

Yale receives grant from Vion

FDA clears Rogaine generic

Procrit cleared for new indication

Biofield seeks approval for new breast cancer diagnostic system

Cambridge NeuroScience/Gladstone Institute AD collaboration

Cephalon files first NDA submission

First NDA submission for NeoPharm seeks approval for two indications

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...